Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?

K Subramaniam, D Yeung, Florian Grimpen, J Joseph, Keith Fay, M Buckland, D. Talaulikar, J Elijah, Andrew C. Clarke, P. Pavli, J. Moore

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)


We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.

Original languageEnglish
Pages (from-to)287-90
Number of pages4
JournalInternal Medicine Journal
Issue number3
Publication statusPublished - Mar 2014
Externally publishedYes


  • Adult
  • Biological Products
  • Humans
  • Immunosuppressive Agents
  • Liver Neoplasms
  • Lymphoma, T-Cell
  • Male
  • Risk Factors
  • Splenic Neoplasms
  • Case Reports
  • Journal Article
  • Review

Cite this